{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:34:59Z","timestamp":1780115699881,"version":"3.54.0"},"reference-count":48,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2006,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Use of positron emission tomography (PET) or PET\/ computed tomography (CT) in Hodgkin lymphoma (HL) continues to expand worldwide. PET is currently widely utilized for response assessment after completion of therapy and, to a lesser extent, for pretreatment staging and assessment of response during therapy (therapy monitoring). In pretreatment staging, PET cannot replace CT or bone marrow biopsy (BMB); however, it can provide complementary information to both CT and BMB, potentially resulting in a modification of disease stage (usually upstaging) in about 15\u201320% of patients with impact on management in about 5\u201315%. PET for response assessment at the conclusion of treatment is substantially more accurate than CT because of its ability to distinguish between viable tumor and necrosis or fibrosis in posttherapy residual mass (es) that are present in about two-thirds of patients with HL without any other clinical or biochemical evidence of disease. PET, therefore, provides more accurate response classifications compared with CT-based assessment. The role of PET for therapy monitoring is still evolving but may prove to be the most exciting with potentially high impact on patient management and outcome. PET evaluation during therapy appears to be at least as accurate for predicting patient outcome as evaluation after completion of therapy and its use is clearly justified if the purpose is to provide an early and yet accurate assessment of response with the clear intent of tailoring therapy according to the information provided by the scan. The role of PET scanning for post-therapy surveillance without clinical, biochemical or radiographic evidence of disease remains controversial, primarily because of the potential for a disproportionate fraction of false-positive findings, potentially resulting in increasing cost without proven benefit from earlier PET detection of disease compared to standard surveillance methods. Large prospective studies are therefore needed to determine whether routine surveillance by PET is both cost-effective and whether it results in meaningful changes in patient management and\/or outcome.<\/jats:p>","DOI":"10.1182\/asheducation-2006.1.259","type":"journal-article","created":{"date-parts":[[2006,11,22]],"date-time":"2006-11-22T23:14:02Z","timestamp":1164237242000},"page":"259-265","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma"],"prefix":"10.1182","volume":"2006","author":[{"given":"Malik E.","family":"Juweid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111704112673100_R1","doi-asserted-by":"crossref","unstructured":"Juweid ME, Cheson BD. Role of positron emission tomography in Lymphoma. J Clin Oncol. 2005;23:4577\u201380.","DOI":"10.1200\/JCO.2005.01.904"},{"key":"2019111704112673100_R2","doi-asserted-by":"crossref","unstructured":"Juweid ME, Cheson BD. Positron emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354:496\u2013507.","DOI":"10.1056\/NEJMra050276"},{"key":"2019111704112673100_R3","doi-asserted-by":"crossref","unstructured":"Friedberg JW, Fishman A, Neuberg D, et al. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. Leuk Lymphoma. 2004;45:85\u201392.","DOI":"10.1080\/1042819031000149430"},{"key":"2019111704112673100_R4","doi-asserted-by":"crossref","unstructured":"Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 1997;203:795\u2013800.","DOI":"10.1148\/radiology.203.3.9169707"},{"key":"2019111704112673100_R5","doi-asserted-by":"crossref","unstructured":"Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology. 1998;206:475\u2013481.","DOI":"10.1148\/radiology.206.2.9457202"},{"key":"2019111704112673100_R6","doi-asserted-by":"crossref","unstructured":"Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer. 2001;91:889\u2013899.","DOI":"10.1002\/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5"},{"key":"2019111704112673100_R7","doi-asserted-by":"crossref","unstructured":"Bangerter M, Moog F, Buchmann I. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin\u2019s disease. Ann Oncol. 1998;9:1117\u20131122.","DOI":"10.1023\/A:1008486928190"},{"key":"2019111704112673100_R8","unstructured":"Jerusalem G, Beguin Y, Fassotte M-F, et al. whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin\u2019s disease. Hematologica. 2001;86:266\u2013273."},{"key":"2019111704112673100_R9","doi-asserted-by":"crossref","unstructured":"Partridge S, Timothy A, O\u2019Doherty MJ, Hain SF, Rankin S, Mikhaeel G. 2-Fluorine-18-fluoro-2-deoxy-D glucose positron emission tomography in the pretreatment staging of Hodgkin\u2019s disease: influence on patient management in a single institution. Ann Oncol. 2000;11:1273\u20131279.","DOI":"10.1023\/A:1008368330519"},{"key":"2019111704112673100_R10","doi-asserted-by":"crossref","unstructured":"Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin\u2019s disease. Ann Hematol. 2002;81:20\u201325.","DOI":"10.1007\/s00277-001-0390-y"},{"key":"2019111704112673100_R11","doi-asserted-by":"crossref","unstructured":"Menzel C, Do\u0308bert N, Mitrou P, et al. Positron emission tomography for the staging of Hodgkin\u2019s lymphoma. Acta Oncologica. 2002;41:430\u2013436.","DOI":"10.1080\/028418602320405014"},{"key":"2019111704112673100_R12","doi-asserted-by":"crossref","unstructured":"Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkin\u2019s lymphoma. Br J Cancer. 2004;90:620\u2013625.","DOI":"10.1038\/sj.bjc.6601561"},{"key":"2019111704112673100_R13","unstructured":"Hutchings M, Loft A, Hansen M, et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkin\u2019s lymphoma. Haematologica. 2006;91:482\u2013489."},{"key":"2019111704112673100_R14","doi-asserted-by":"crossref","unstructured":"Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging \u2013 do we need contrast-enhanced CT? Radiology. 2004;232:823\u2013829.","DOI":"10.1148\/radiol.2323030985"},{"key":"2019111704112673100_R15","doi-asserted-by":"crossref","unstructured":"Moog F, Bangerter M, Kotzerke J, Guhlmann A, Frickhofen N, Reske SN. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998;16:603\u2013609.","DOI":"10.1200\/JCO.1998.16.2.603"},{"key":"2019111704112673100_R16","doi-asserted-by":"crossref","unstructured":"Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998;91:3340\u20133346.","DOI":"10.1182\/blood.V91.9.3340"},{"key":"2019111704112673100_R17","doi-asserted-by":"crossref","unstructured":"Elstrom R, Guan L, Baker G, et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood. 2003;101:3875\u20133876.","DOI":"10.1182\/blood-2002-09-2778"},{"key":"2019111704112673100_R18","unstructured":"Pakos EE, Fotopoulos AD, Ioannidis JPA. 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med. 2005;46:958\u2013963."},{"key":"2019111704112673100_R19","doi-asserted-by":"crossref","unstructured":"Allen-Auerbach M, Quon A, Weber WA, et al. Comparison between 2-deoxy-2-[(18)F]fluoro-D-glucose positron-emission tomography and positron-emission tomography\/ computed tomography hardware fusion for staging of patients with lymphoma. Mol Imaging Biol. 2004;6:411\u2013416.","DOI":"10.1016\/j.mibio.2004.08.004"},{"key":"2019111704112673100_R20","doi-asserted-by":"crossref","unstructured":"Meyer RM, Cospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited stage Hodgkin\u2019s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol. 2005;23:4634\u20134642.","DOI":"10.1200\/JCO.2005.09.085"},{"key":"2019111704112673100_R21","doi-asserted-by":"crossref","unstructured":"Sieber M, Engert A, Diehl V. Treatment of Hodgkin\u2019s disease: results and current concepts of the German Hodgkin\u2019s Lymphoma Study Group. Ann Oncol. 2000;11(Suppl 1):S81\u201385.","DOI":"10.1093\/annonc\/11.suppl_1.S81"},{"key":"2019111704112673100_R22","doi-asserted-by":"crossref","unstructured":"Freudenberg LS, Antoch G, Schu\u0308tt P, et al. FDG-PET\/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging. 2004;31:325\u2013329.","DOI":"10.1007\/s00259-003-1375-y"},{"key":"2019111704112673100_R23","doi-asserted-by":"crossref","unstructured":"Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94:429\u2013433.","DOI":"10.1182\/blood.V94.2.429"},{"key":"2019111704112673100_R24","doi-asserted-by":"crossref","unstructured":"Zinzani PL, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol. 1999;10:1181\u20131184.","DOI":"10.1023\/A:1008327127033"},{"key":"2019111704112673100_R25","doi-asserted-by":"crossref","unstructured":"Bangerter M, Moog F, Griesshammer M, et al. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol. 1999;38:799\u2013804.","DOI":"10.1080\/028418699432969"},{"key":"2019111704112673100_R26","doi-asserted-by":"crossref","unstructured":"Mikhaeel NG, Timothy AR, Hain SF, O\u2019Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol. 2000;11 Suppl 1:147\u2013150.","DOI":"10.1093\/annonc\/11.suppl_1.S147"},{"key":"2019111704112673100_R27","doi-asserted-by":"crossref","unstructured":"de Wit M, Bohuslavizki KH, Buchert R, et al. 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin\u2019s lymphoma. Ann Oncol. 2001;12:29\u201337.","DOI":"10.1023\/A:1008357126404"},{"key":"2019111704112673100_R28","doi-asserted-by":"crossref","unstructured":"Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin\u2019s disease and non-Hodgkin\u2019s lymphoma. Br J Haematol. 2001;115:793\u2013800.","DOI":"10.1046\/j.1365-2141.2001.03147.x"},{"key":"2019111704112673100_R29","doi-asserted-by":"crossref","unstructured":"Weihrauch MR, Re D, Scheidhauer K, et al. Thoracic positron emission tomography using 18F-fluorodeoxyglucose for the evaluation of residual mediastinal Hodgkin disease. Blood. 2001;98:2930\u20132934.","DOI":"10.1182\/blood.V98.10.2930"},{"key":"2019111704112673100_R30","doi-asserted-by":"crossref","unstructured":"Dittman H, Sokler M, Kollmannsberger C, et al. Comparison of 18FDG-PET with CT scans in the evaluation of patients with residual and recurrent Hodgkin\u2019s lymphoma. Oncol Rep. 2001;8:1393\u20131399.","DOI":"10.3892\/or.8.6.1393"},{"key":"2019111704112673100_R31","doi-asserted-by":"crossref","unstructured":"Spaepen K, Stoobants S, Dupont P, et al. Can positron emission tomography with [(18)F]-fluorodeoxyglucose after first-line treatment distinguish Hodgkin\u2019s disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? Br J Haematol. 2001;115:272\u2013278.","DOI":"10.1046\/j.1365-2141.2001.03169.x"},{"key":"2019111704112673100_R32","doi-asserted-by":"crossref","unstructured":"Hueltenschmidt B, Sautter-Bihl ML, Lang O, et al. Whole body positron emission tomography in the treatment of Hodgkin disease. Cancer. 2001;91:302\u2013310.","DOI":"10.1002\/1097-0142(20010115)91:2<302::AID-CNCR1002>3.0.CO;2-4"},{"key":"2019111704112673100_R33","unstructured":"Zijlstra JM, Linduer-vander Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica. 2006;91:522\u2013529."},{"key":"2019111704112673100_R34","doi-asserted-by":"crossref","unstructured":"Canellos GP. Residual mass in lymphoma may not be residual disease. J Clin Oncol. 1988;6:931\u2013 933.","DOI":"10.1200\/JCO.1988.6.6.931"},{"key":"2019111704112673100_R35","unstructured":"Juweid ME, Stroobants S, Mottaghy, et al. Recommendations of the imaging committee of the International Harmonization Project (IHP) for FDG-PET (PET) use in patients with lymphoma. J Nucl Med. 2006;47:452. Abstract #1681."},{"key":"2019111704112673100_R36","unstructured":"Olsen KA, Sohi JS, Abraham T, Juweid M. Initial Validation of Standardized Qualitative (visual) criteria for FDG-PET assessment of residual masses following lymphoma therapy. Proceedings of 2006 Radiological Society of North America Annual Meeting. In press."},{"key":"2019111704112673100_R37","doi-asserted-by":"crossref","unstructured":"Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphomas from the members of the International Harmonization Project (IHP) of the Competence Network Malignant Lymphoma. Proc ASCO. 2006; Abstract.","DOI":"10.1182\/blood.V106.11.18.18"},{"key":"2019111704112673100_R38","doi-asserted-by":"crossref","unstructured":"Juweid ME, Wiseman G, Vose JM, et al. Response assessment of aggressive non-Hodgkin\u2019s lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyclucose positron emission tomography. J Clin Oncol. 2005;23:4652\u20134661.","DOI":"10.1200\/JCO.2005.01.891"},{"key":"2019111704112673100_R39","doi-asserted-by":"crossref","unstructured":"Surbone A, Longo DL, DeVita VT Jr., et al. Residual abdominal masses in aggressive non-Hodgkin\u2019s lymphoma after combination chemotherapy: significance and management. J Clin Oncol. 1988;6:1832\u20131837.","DOI":"10.1200\/JCO.1988.6.12.1832"},{"key":"2019111704112673100_R40","doi-asserted-by":"crossref","unstructured":"Fuks JZ, Aisner J, Wiernik PH. Restaging laparotomy in the management of the non-Hodgkin\u2019s lymphomas. Med Pediatr Oncol. 1982;10:429\u2013438.","DOI":"10.1002\/mpo.2950100502"},{"key":"2019111704112673100_R41","doi-asserted-by":"crossref","unstructured":"Coiffier B, Gisselbrecht C, Herbrecht R, et al. LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma. J Clin Oncol. 1989;7:1018\u20131026.","DOI":"10.1200\/JCO.1989.7.8.1018"},{"key":"2019111704112673100_R42","unstructured":"Ro\u0308mer W, Hanauske A-R, Ziegler S, et al. Positron emission tomography in non-Hodgkin\u2019s lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Blood. 1998;91:4464\u20134471."},{"key":"2019111704112673100_R43","unstructured":"Kostakoglu L, Coleman M, Leonard JP, et al. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin\u2019s disease. J Nucl Med. 2002;43:1018\u20131027."},{"key":"2019111704112673100_R44","doi-asserted-by":"crossref","unstructured":"Spaepen K, Stroobants S, Dupont P, et al. Early staging positron emission tomography (PET) with fluorine 18 fluorodeoxyglucose ([18F]FDG) predicts outcome in patients with aggressive non-Hodgkin\u2019s lymphoma. Blood. 2001;98:726a.","DOI":"10.1093\/annonc\/mdf256"},{"key":"2019111704112673100_R45","doi-asserted-by":"crossref","unstructured":"Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol. 2005;16:1160\u20138.","DOI":"10.1093\/annonc\/mdi200"},{"key":"2019111704112673100_R46","doi-asserted-by":"crossref","unstructured":"Hutchings M, Loft A, Hansen M, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52\u20139.","DOI":"10.1182\/blood-2005-06-2252"},{"key":"2019111704112673100_R47","unstructured":"Jerusalem G, Beguin Y, Fassotte MF, et al: Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin\u2019s lymphoma. Haematologica. 2000;85:613\u20138."},{"key":"2019111704112673100_R48","doi-asserted-by":"crossref","unstructured":"Jerusalem G, Beguin Y, Fassotte MF, et al. Early detection of relapse by whole-body emission tomography in the follow-up of patients with Hodgkin\u2019s disease. Ann Oncol. 2003;14:123\u2013130.","DOI":"10.1093\/annonc\/mdg011"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/259\/1091526\/259_265ash.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2006\/1\/259\/1091526\/259_265ash.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T19:57:53Z","timestamp":1683662273000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2006\/1\/259\/19764\/Utility-of-Positron-Emission-Tomography-PET"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,1]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,1,1]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2006.1.259","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,1]]}}}